InvestWiser

Vicore Pharma Holding AB (publ)

VICONasdaq StockholmHealthcareMarket value 2.9 bn SEK
10.24SEK −0.4%
last day · Price as of 19 November 2026

The answer first

Does Vicore Pharma Holding beat the market?

No, Vicore Pharma Holding has not beaten the market over the last year.

Vicore Pharma Holding+1.2%Stockholm (OMXSGI)+17.7%
  • The ranking · Quality, value and trend combined

    Better than 16% of Nordic stocks

    • Quality60
    • Value3
    • Trend32

    No. 146 of 195 in healthcare

Max for seven days

Follow Vicore Pharma Holding with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Vicore Pharma Holding

From today, at a price of 10.24 SEK. Write why you follow Vicore Pharma Holding, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Vicore Pharma Holding

Your first answer is free, no account needed.

Do you own Vicore Pharma Holding, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Vicore Pharma Holding and a few more. Free, no card.

Past year against the exchange and Super Stock
Vicore Pharma Holding+1.2%Stockholm (OMXSGI)+17.7%Super Stock+46.3%
18 November 202519 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Vicore Pharma Holding has risen 1.2% over the past year, including dividends.
  • Overall, Vicore Pharma Holding ranks better than 16% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 82.4%. The price is 71.9% below its peak now.

What do analysts think of Vicore Pharma Holding?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

16

Quality, value and trend together. Better than 16% of Nordic stocks.

No. 146 of 195 in healthcare

Quality60
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 108 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.00
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−70.7%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value3
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 174 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity3.9
  • P/SPrice divided by sales742.3
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend32
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 104 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−6.5%
  • 6 months−16.7%
  • 9 months−4.3%
  • 12 months+1.2%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+11.7%
3 years, per year
−7.2%
5 years, per year
−9.1%
10 years, per year
+1.7%
Largest fall, 3 years
−82.4%
From a peak to the bottom
From the peak now
−71.9%
How far the price is from the peak
Volatility, 1 year
54.3%
How much the price swings over a year
Beta, 1 year
1.35
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Vicore Pharma Holding

10 funds we follow own Vicore Pharma Holding. The share is how much of the fund the stock makes up.

  • Norway1
  • Sweden9

From the funds' latest known holdings.

About Vicore Pharma Holding

Vicore Pharma Holding AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 50 employees.

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.

See the full analysis of Vicore Pharma Holding.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market